| Title |
Date |
Location |
Send to a Colleague |
| Personalized Medicine Coalition |
Oct 16, 2008 |
The Ohio State University Medical Center
|
|
WHENOctober 16 7:30 AM - October 17, 2008 1:00 PM
WHERE
The Ohio State University Medical Center
Center for Continuing Medical Education
Suite 206 Atwell Hall
453 W. 10th Avenue
Columbus, Ohio 43210
Map
SUMMARYPersonalized health care is emerging as the single most-significant development in health care in the 21st century. It springs forth from the recent sequencing of the human genome, major technical advances that facilitate our ability to understand the uniqueness of each individual at the molecular level, and advances in the field of bioinformatics. Michael Leavitt, Secretary of the U.S. Department of Health and Human Services (DHHS), defines personalized health care as: “the basic scientific breakthroughs of the human genome with computer-age ability to exchange and manage data. Increasingly it will give us the ability to deliver the right treatment to the right patient at the right time - every time.”
[Learn More]
|
| ACC Annual Meeting '08 |
Oct 19, 2008 |
Washington State Convention & Trade Center
|
|
Informed. In-house. Indispensable.
WHENOctober 19 6:00 PM - October 22, 2008 12:30 PM
WHERE
Washington State Convention & Trade Center
800 Convention Place
Seattle, WA 98101
Map
SUMMARYFoley Hoag is a proud Gold Sponsor of the ACC's 2008 Annual Meeting. Visit our booth on the exhibition floor, and attend sessions featuring Foley Hoag lawyers.
- Session 113: In-house Counsel as Circus Ringmaster, on Monday, October 20 from 11:00 a.m.-12:30 p.m. Michael Keating from Foley Hoag will join this panel in the Global/International Legal Affairs program track.
- Session 202: The Tricks & Traps of Corporate Intrapreneurship & Entrepreneurial Investment: Getting the Most Out of a New Business, on Monday, October 20 from 2:30-4:00 p.m. This program will be moderated by Foley Hoag Partner Peter Rosenblum and will be presented as part of the Small Law Department track.
Stay tuned to this page for more information on what Foley Hoag has planned for ACC's 2008 Annual Meeting.
[Learn More]
|
| Molecular Diagnostics |
Oct 20, 2008 |
Manchester Grand Hyatt Hotel
|
|
WHENOctober 20 7:30 PM - October 22, 2008 4:00 PM
WHERE
Manchester Grand Hyatt Hotel
One Market Place
San Diego, CA 92101
Map
[Learn More]
|
| TCN: Funding Expedition™ Mixer |
Nov 6, 2008 |
Foley Hoag LLP (Boston Office)
|
|
WHENNovember 6, 2008 5:30 PM - 8:00 PM
WHERE
Foley Hoag LLP (Boston Office)
Seaport World Trade Center West
155 Seaport Boulevard
Boston, MA 02210-2600
Map
SUMMARYAre you an entrepreneur wanting to learn more about navigating New England’s business and funding landscape? Are you an investor seeking to mentor and become even more integrated in New England’s entrepreneurial community? Save this date to bring your ideas to a (free) networking event with entrepreneurial experts!
[Learn More]
|
| American Conference Institute’s 11th Advanced Forum on Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements: Allocating Rights, Responsibilities & Rewards in Licensing, Strategic Alliances and Partnering Deals |
Nov 12, 2008 |
Helmsley Park Lane Hotel
|
|
WHENNovember 12 7:30 AM - November 13, 2008 3:00 PM
WHERE
Helmsley Park Lane Hotel
36 Central Park S
New York, NY 10019
Map
SUMMARYWith pipelines drying up, patent expirations at an all time high and R&D costs through the roof, the stakes in negotiating and maintaining lucrative licensing and collaborations could not be higher. But as the critical nature of these deals increases, so do the challenges and complexities.
Competition is increasing, laws are changing, and M&A activity is heating up. Further, IP valuation contingencies are arising in the wake of the Supreme Court's MedImmune decision, and parties are seeking greater protection for their IP rights and looking to draft termination provisions that allow both parties to walk away with their assets intact. In addition, selecting the right partners, deal structure and compensation analysis are crucial to the success of the deal, and an assessment of these factors must be done early in the process. Lastly, as biotech/pharma look more and more to collaborate with the government and institutional researchers for a competitive edge, they face a distinct culture clash that leads to wheel-spinning, preventing agreements from being reached.
Unlike any other licensing event, you will not only get the opportunity to network with and learn from a diverse, front-line faculty of experienced in-house counsel, licensing and business development executives from leading pharmaceutical and biotech companies, but you will also receive practical guidance on how to translate new laws and trends into a winning business strategy and overcome challenges and complexities in negotiating and maintaining the best deal available for your company's needs.
[Learn More]
|